About the Study
This study is designed to evaluate the safety and effectiveness of RO7795068, an investigational injection, for chronic weight management in adults with type 2 diabetes mellitus (T2DM) who have obesity or who are overweight. RO7795068 is thought to work on natural hormone pathways involved in appetite and metabolism, and it is given as a once-weekly injection under the skin using an auto-injector.
The study is randomized, double-blind, and placebo-controlled to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 75% chance you will receive the study treatment and a 25% chance you will receive a placebo. A placebo is an inactive material that looks like the study drug but does not contain any active ingredient.
You will be in this study for approximately 79 weeks which will include a screening period, a treatment period, and a follow up period. The study will require up to 16 in-clinic visits and 6 remote visits, lifestyle counseling, and completion of questionnaires or diaries. If you qualify and choose to participate, you may be compensated up to $3,572 for your study-related time and travel. There may also be a possibility to join an open label extension following participation where the active drug will be received for anyone completing the core study. Your participation is entirely voluntary, and you can leave the study at any time.